4-chloro-2-(methylaminomethyl)aniline | 748806-37-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-2-(methylaminomethyl)aniline
• 英文别名: 4-chloro-2-methylaminomethyl-phenylamine；(2-amino-5-chlorobenzyl)methylamine
• CAS: 748806-37-3
• 化学式: C₈H₁₁ClN₂
• 分子量: 170.642
• InChiKey: ROHOPJILCIIOET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-2-(methylaminomethyl)aniline 、 trans-2-(chloromethyl)-5-[4-(2-pyridyloxy)cyclohexyl]-1,3,4-oxadiazole 在 碳酸氢钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 26.5h， 生成 trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene
  参考文献：
  名称：

  [EN] SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF
  [FR] SYNTHÈSE DE TRANS-8-CHLORO-5-MÉTHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4 H-2,3,5,10B-TÉTRAAZA-BENZO[E]AZULÈNE ET LEURS FORMES CRISTALLINES

  摘要：

  本发明提供了制备取代的l-[4-(吡啶-2-氧基)-环己基]-5,6-二氢-4H-2,3,5,10b-四氮杂苯并[e]吖啶的工艺。还公开了在本发明方法中作为中间体有用的化合物。

  公开号：

  WO2015082370A1
• 作为产物：
  描述：

  5-氯-2-硝基苯甲醛 在 甲醇 、 sodium tetrahydroborate 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、100.0 kPa 条件下， 反应 5.0h， 生成 4-chloro-2-(methylaminomethyl)aniline
  参考文献：
  名称：

  [EN] SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF
  [FR] SYNTHÈSE DE TRANS-8-CHLORO-5-MÉTHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4 H-2,3,5,10B-TÉTRAAZA-BENZO[E]AZULÈNE ET LEURS FORMES CRISTALLINES

  摘要：

  本发明提供了制备取代的l-[4-(吡啶-2-氧基)-环己基]-5,6-二氢-4H-2,3,5,10b-四氮杂苯并[e]吖啶的工艺。还公开了在本发明方法中作为中间体有用的化合物。

  公开号：

  WO2015082370A1
• 作为试剂：
  描述：

  4-chloro-2-(methylaminomethyl)aniline 、 trans-2-(chloromethyl)-5-[4-(2-pyridyloxy)cyclohexyl]-1,3,4-oxadiazole 在 4-chloro-2-(methylaminomethyl)aniline 作用下， 生成 trans-4-chloro-2-[[methyl-[[5-[4-(2-pyridyloxy)cyclohexyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]aniline
  参考文献：
  名称：

  [EN] SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF
  [FR] SYNTHÈSE DE TRANS-8-CHLORO-5-MÉTHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4 H-2,3,5,10B-TÉTRAAZA-BENZO[E]AZULÈNE ET LEURS FORMES CRISTALLINES

  摘要：

  本发明提供了制备取代的l-[4-(吡啶-2-氧基)-环己基]-5,6-二氢-4H-2,3,5,10b-四氮杂苯[e]蓝的工艺。本发明还揭示了在本发明方法中有用的中间体化合物。

  公开号：

  WO2015082370A1

文献信息

• [EN] TRIAZOLE COMPOUNDS USEFUL IN THERAPY<br/>[FR] COMPOSES DE TRIAZOLE UTILISES EN THERAPIE
  申请人：PFIZER LTD

  公开号：WO2004074291A1

  公开（公告）日：2004-09-02

  A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents -(CH2)d(O)e-, -CO-, or -CH(C1-6 alkyl)-; W is -0-, -S(O)a , or -N(R1')-R1 represents H, C 1-6 alkyl, (CH2)bCOR2, CO(CH2)bNR2R3, S02R2, (CH2 )cOR2, (CH2)c,NR2R3, or (CH2)bhet1; het1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C 1-6 alkyl; X and Y independently represent H, C 1-6 alkyl, halogen, OH, CF3, OCF3, OR4; Z represents -(CH2)f(O)g , -CO- or -CH(C 1-6 alkyl)-; Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH2, CF3, OCF3, and in which optionally at least one ring N is substituted with O; R2 and R3 independently represent H, C 1-6 alkyl [optionally substituted with OH, halogen,N(C 1.6 alkyl)2, or C 1.6 alkyloxy], C 1.6 alkyloxy, N(C 1-6 alkyl)2, or [C 3-8 cycloalkyl]; or R2 and R3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C 1-6 alkyl;R4 represents straight or branched C 1-6 alkyl, a and c independently represent 0, 1, or 2; b, e and g independently represent 0 or 1; d and f independently represent 1 or 2;are useful in the treatment of dysmenorrhoea.

  式(I)的化合物，或其药学上可接受的衍生物，其中V代表-(CH2)d(O)e-, -CO-,或-CH(C1-6烷基)-；W为-0-, -S(O)a,或-N(R1')-R1代表H，C1-6烷基，(CH2)bCOR2，CO(CH2)bNR2R3，S02R2，(CH2)cOR2，(CH2)c,NR2R3，或(CH2)bhet1；het1代表一个饱和或不饱和的含有3至8个原子的杂环，其中含有一个或多个从O、N或S中选择的杂原子，可选择地用C1-6烷基取代；X和Y独立地代表H，C1-6烷基，卤素，OH，CF3，OCF3，或OR4；Z代表-(CH2)f(O)g，-CO-或-CH(C1-6烷基)-；环A代表一个4-7成员的饱和N-含杂环，可选择地用OH取代，并且其中可选择地至少一个环N用O取代；环B代表苯或一个4-7成员的不饱和N-含杂环，可选择地用OH，卤素，CN，CONH2，CF3，OCF3取代，并且其中可选择地至少一个环N用O取代；R2和R3独立地代表H，C1-6烷基[可选择地用OH，卤素，N(C1-6烷基)2，或C1-6烷氧基取代]，C1-6烷氧基，N(C1-6烷基)2，或[C3-8环烷基]；或R2和R3，连同它们附着的氮原子，独立地代表一个含有3至8个原子的杂环，可选择地用C1-6烷基取代；R4代表直链或支链C1-6烷基，a和c独立地代表0，1，或2；b，e和g独立地代表0或1；d和f独立地代表1或2；在痛经的治疗中是有用的。
• [EN] COMPOUNDS USEFUL IN THERAPY<br/>[FR] COMPOSES UTILES EN THERAPIE
  申请人：PFIZER LTD

  公开号：WO2005068466A1

  公开（公告）日：2005-07-28

  Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein: X represents NR or O; R represents hydrogen, C1-8 alkyl or SO2[C,1-8 alkyl]; W represents N or CH; Y and Y' independently represent hydrogen, halogen, OH, CF3, OCF3, CN, NH2 C1-8 alkyl, C1-8 alkyloxy or C3-8cycloalkyl; Ring A represents a heterocyclic ring containing at least one nitrogen atom; Z represents a direct link, C1-8 alkyl or C3-8 cycloalkyl; R1 represents R2, OR2, OR 3-R4, N(R2)[C1-8 alkylene]aR4; NCOR2, or SR4; R2 and R4 independently represent hydrogen, C3-8 cycloalkyl, CF3, Ar or Het; R3 represents a direct link or C1-8 alkyl; is 0 or 1; Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a heterocyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below; at each occurrence C1-8alkyl, C1-8alkylene and C3-8cycloalkyl may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het, C1-8alkyl, C1-8alkylene and C3-8cycloalkyl referred to the above are independently selected from hydrogen, halogen, C1-8alkyl, C1-8alkyloxy, S[C1-8alkyl], CN, CF3, NH2 and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

  式(I)的化合物，或其在药学上可接受的衍生物中，其中：X代表NR或O；R代表氢，C1-8烷基或SO2[C,1-8烷基]；W代表N或CH；Y和Y'独立地代表氢，卤素，羟基，三氟甲基，三氟甲氧基，氰基，NH2，C1-8烷基，C1-8烷氧基或C3-8环烷基；环A代表至少含有一个氮原子的杂环；Z代表直链，C1-8烷基或C3-8环烷基；R1代表R2，OR2，OR3-R4，N(R2)[C1-8烷基]aR4；NCOR2或SR4；R2和R4独立地代表氢，C3-8环烷基，三氟甲基，芳基或杂环基；R3代表直链或C1-8烷基；a为0或1；Ar代表芳香环，可选择与杂环环融合，并/或可选择使用下述一个或多个基团进行取代；Het代表杂环环，可选择使用下述一个或多个基团进行取代，并/或可选择与一个可选择使用下述一个或多个基团进行取代的芳香环融合；在每次出现时，C1-8烷基，C1-8烷基烯和C3-8环烷基可以独立地选择使用下述一个或多个基团进行取代；对于Ar，Het，C1-8烷基，C1-8烷基烯和C3-8环烷基的取代基团如上所述是独立选择自氢，卤素，C1-8烷基，C1-8烷氧基，S[C1-8烷基]，氰基，三氟甲基，NH2和羟基；适用于治疗焦虑症，心血管疾病（包括心绞痛，动脉粥样硬化，高血压，心力衰竭，水肿，高钠血症），月经疼痛（原发性和继发性），子宫内膜异位症，呕吐（包括晕动病），子宫内生长迟缓，炎症（包括类风湿关节炎），中期疼痛，子痫前症，早泄，早产（早产）和雷诺病。
• Triazole compounds useful in therapy
  申请人：Bryans Stephen Justin

  公开号：US20060194794A1

  公开（公告）日：2006-08-31

  A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  一种化合物的公式（I），或其药学上可接受的衍生物，其中A、B、V、W、X、Y和Z的定义如本文所述；其制药组合物；以及其用途。
• Compounds useful in therapy
  申请人：Ryckmans Thomas

  公开号：US20070167430A1

  公开（公告）日：2007-07-19

  Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein: X represents NR or O; R represents hydrogen, C 1-8 alkyl or SO 2 └C, 1-8 alkyl┘; W represents N or CH; Y and Y′ independently represent hydrogen, halogen, OH, CF 3 , OCF 3 , CN, NH 2 C 1-8 alkyl, C 1-8 alkyloxy or C 3-8 cycloalkyl; Ring A represents a heterocyclic ring containing at least one nitrogen atom; Z represents a direct link, C 1-8 alkyl or C 3-8 cycloalkyl; R 1 represents R 2 , OR 2 , OR 3 —R 4 , N(R 2 )[C 1-8 alkylene] a R 4 ; NCOR 2 , or SR 4 ; R 2 and R 4 independently represent hydrogen, C 3-8 cycloalkyl, CF 3 , Ar or Het; R 3 represents a direct link or C 1-8 alkyl; is 0 or 1; Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a heterocyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below; at each occurrence C 1-8 alkyl, C 1-8 alkylene and C 3-8 cycloalkyl may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het, C 1-8 alkyl, C 1-8 alkylene and C 3-8 cycloalkyl referred to the above are independently selected from hydrogen, halogen, C 1-8 alkyl, C 1-8 alkyloxy, S[C 1-8 alkyl], CN, CF 3 , NH 2 and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

  化合物的式子（I），或其药学上可接受的衍生物，其中：X代表NR或O; R代表氢，C1-8烷基或SO2└C，1-8烷基┘; W代表N或CH; Y和Y′分别代表氢，卤素，OH，CF3，OCF3，CN，NH2C1-8烷基，C1-8烷氧基或C3-8环烷基; 环A表示至少含有一个氮原子的杂环; Z表示直接连接，C1-8烷基或C3-8环烷基; R1表示R2，OR2，OR3—R4，N（R2）[C1-8烷基]aR4; NCOR2，或SR4; R2和R4分别表示氢，C3-8环烷基，CF3，Ar或Het; R3表示直接连接或C1-8烷基; 为0或1; Ar表示芳香环，可选地与杂环融合，并/或可选地用下述一种或多种基团进行取代; Het表示杂环，可选地用下述一种或多种基团进行取代，并/或可选地与可选地用下述一种或多种基团进行取代的芳香环融合; 在每次出现中，C1-8烷基，C1-8烷基和C3-8环烷基可以独立地用下述一种或多种基团进行取代; 上述Ar，Het，C1-8烷基，C1-8烷基和C3-8环烷基的取代基团是独立选择的，包括氢，卤素，C1-8烷基，C1-8烷氧基，S[C1-8烷基]，CN，CF3，NH2和OH; 用于治疗焦虑症，心血管疾病（包括心绞痛，动脉粥样硬化，高血压，心力衰竭，水肿，高钠血症），痛经（原发性和继发性），子宫内膜异位症，呕吐（包括晕动病），宫内生长迟缓，炎症（包括类风湿性关节炎），中间痛，先兆子痫，早泄，早产和雷诺病。
• Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof
  申请人：Hoffmann-La Roche Inc.

  公开号：US10246460B2

  公开（公告）日：2019-04-02

  The present invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

  本发明提供了制造取代的 1-[4-(吡啶-2-氧基)-环己基]-5,6-二氢-4H-2,3,5,10b-四氮杂苯并[e]氮烯的工艺。本发明还公开了可用作本发明方法中间体的化合物。